Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique

American Journal of Psychiatry

Volumn 155, Issue 8, 1998, Pages 1113-1116

  Hasan, Samia ^b   Buckley, Peter ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEMENTIA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; FEMALE; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DEFICIENCY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; SCHIZOPHRENIA;

EID: 0031850514     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.8.1113     Document Type: Article

References (36)

1. Weller M, Kornhuber J: Does clozapine cause neuroleptic malignant syndrome? J Clin Psychiatry 1993; 54:70-71
2. Thornberg SA, Ereshefsky L: Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy 1993; 13:510-514
3. Sachdev P, Kruk J, Kneebone M, Kissane D: Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995; 15:365-371
4. Nierenberg D, Disch M, Manheimer E, Patterson J, Ross J, Silvestri G, Summerhill E: Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome. Clin Pharmacol Ther 1991; 50:580-586
5. Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185-202
6. Levenson JL: Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-1145
7. Pope HG Jr, Cole JO, Choras PT, Fulwiler CE: Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174:493-495
8. Muller T, Becker T, Fritze J: Neuroleptic malignant syndrome after clozapine plus carbamazepine (letter). Lancet 1988; 2: 8626-8627
9. Nopoulos P, Flaum M, Miller DD: Atypical neuroleptic malignant syndrome with an atypical neuroleptic: clozapine-induced NMS without rigidity. Ann Clin Psychiatry 1990; 2:251-253
10. Miller DD, Sharafuddin MJA, Kathol RG: A case of clozapine-induced NMS wihtout rigidity. Ann Clin Psychiatry 1990; 2:251-253
11. Anderson ES, Powers PS: Neuroleptic malignant syndrome associated with clozapine use. J Clin Psychiatry 1991; 52:102-104
12. DasGupta K, Young A: Clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991; 52:105-107
13. Goates MG, Escobar JI: An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge (letter). J Clin Psychopharmacol 1992; 12:139-140
14. Reddig S, Minnema AM, Tandon R: Neuroleptic malignant syndrome and clozapine. Ann Clin Psychiatry 1993; 5:25-27
15. Nemecek D, Rastogi-Cruz D, Csernansky JG: Atropinism may precipitate neuroleptic malignant syndrome during treatment with clozapine (letter). Am J Psychiatry 1993; 150:1561; correction, 150:1910
16. Viner MW, Escobar JI: An apparent neurotoxicity associated with clozapine (letter). J Clin Psychiatry 1994; 55:38-39
17. Tsai G, Crisostomo G, Rosenblatt ML, Stern TA: Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995; 7:91-95
18. Lowy A, Wilson A, Sachdev P, Lindeman R: Disseminated intravascular coagulopathy and thrombocytopenia associated with clozapine-induced neuroleptic malignant syndrome (letter). Aust NZ J Med 1995; 25:368
19. Ganelin L, Lichtenberg PS, Marcus EL, Munter RG: Suspected neuroleptic malignant syndrome in a patient receiving clozapine. Ann Pharmacother 1996; 30:248-250
20. Illing M, Ancill R: Clozapine-induced neuroleptic malignant syndrome: clozapine monotherapy rechallenge in a case of previous NMS (letter). Can J Psychiatry 1996; 41:258
21. Tomsic J, Chatt PL, Chandarana P: Neuroleptic malignant syndrome caused by risperidone (poster). 25th Annual Professional Practice Conference of the Canadian Society of Hospital Pharmacists 1994:N10314/1
22. Lee H, Ryan J, Mullett G, Lawlor BA: Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Hum Psychopharmacol 1994: 9:303-305
23. Webster P, Wijeratne C: Risperidone-induced neuroleptic malignant syndrome (letter). Lancet 1994; 344:1228-1229
24. Raitasuo V, Vataja R, Elomaa E: Risperidone-induced neuroleptic malignant syndrome in a young patient [letter). Lancet 1994; 344:1705
25. Dave M: Two cases of risperidone-induced neuroleptic malignant syndrome (letter). Am J Psychiatry 1995; 152:1233-1234
26. Singer S, Richards C, Boland RJ: Two cases of risperidone-induced neuroleptic malignant syndrome (letter). Am J Psychiatry 1995; 152:1234
27. Murray S, Haller E: Risperidone and NMS? (letter). Psychiatr Serv 1995; 46:951
28. Najara JE, Enikeev ID: Risperidone and neuroleptic malignant syndrome: a case report (letter). J Clin Psychiatry 1995; 56: 534-535
29. Meterissian GB: Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry 1996; 41:52-54
30. Tarsy D: Risperidone and neuroleptic malignant syndrome (letter). JAMA 1996; 275:446
31. Kern JL, Cernek PK: Delayed risperidone-induced neuroleptic malignant syndrome (letter). Ann Pharmacother 1996; 30:300
32. Levin GM, Lazowick AL, Powell HS: Neuroleptic malignant syndrome with risperidone (letter). J Clin Psychopharmacol 1996; 16:192-193
33. Buckley PF, Meltzer HY: Treatment of schizophrenia, in A Textbook of Psychopharmacology. Edited by Schatzberg A, Nemeroff CD. Washington, DC, American Psychiatric Press, 1995, pp 615-639
34. Scelsa SN, Simpson DM, McQuistion HL, Fineman A, Ault K, Reichler B: Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 1996; 47:1518-1523
35. Addonizio G, Susman VL, Roth SD: Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987; 22:1004-1020
36. Nyberg S, Farde L. Halldin C: Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Arch Gen Psychiatry 1997; 54:953-958